Insights into Digital Therapeutics Space and Associated Evidence Thresholds

Diana Brixner, PhD, FAMCP, of the University of Utah opens a discussion surrounding digital therapeutics.

Dr Brixner expands on evidence thresholds in the digital therapeutic space.

Diana Brixner, PhD, FAMCP, examines the payer perspective on including Prescription Digital Therapeutics in formularies, utilizing real-world evidence as a key metric to assess the impact, cost-effectiveness, and patient benefit of these innovative digital treatments.

A medical expert explores the development of prescription digital therapeutic models, including insurance investment in prescription digital therapeutics and telemedicine, as well as employer-sponsored benefits for non-prescription digital therapeutics and wellness initiatives aimed at improving overall health outcomes.